How much funding has Cardurion raised?

Cardurion has raised $820.0M in total funding, most recently a Series B round.

Who are Cardurion's investors?

Cardurion's investors include Polaris Partners, Bain Capital Life Sciences, Ascenta Capital, GV, Bain Capital Private Equity, Takeda (JP).

Where is Cardurion headquartered?

Cardurion is headquartered in Burlington, Massachusetts, United States.

What industry is Cardurion in?

Cardurion operates in Biotech, Healthcare.

Cardurion

formerly Cardurion Pharmaceuticals

Changing the Course of Cardiovascular Disease.

Burlington, United States · Founded 2017 · $820.0M raised

Biotech

Healthcare

Headquarters: Burlington, Massachusetts
Employees: 11–50
Founded: 2017
Business Model: B2B

Website: cardurion.com
Total Funding: $820.0M
Last Round: $260.0M Series BJul 2024
Rounds: 10

About

Cardurion Pharmaceuticals is a clinical-stage biotechnology company pioneering next-generation therapeutics for cardiovascular disease. The company has two active clinical programs: a PDE9 inhibitor (CRD-750) in Phase 2 trials for heart failure, and a CaMKII inhibitor for rare arrhythmias including catecholaminergic polymorphic ventricular tachycardia (CPVT) and broader cardiovascular indications. Founded by physician-scientist Dr. Michael E. Mendelsohn, Cardurion is backed by Bain Capital Life Sciences, headquartered in Burlington, Massachusetts with a research affiliate in Japan.

Summary

Cardurion is a Biotech company based in Burlington, United States, founded in 2017. It has raised $820.0M in total across 10 rounds, most recently a $260.0M Series B round in Jul 2024. Investors include Polaris Partners, Bain Capital Life Sciences and Ascenta Capital.